| In general, there is no greater risk of severe SARS-CoV-2 infection in immune thrombocytopenia (ITP) patients than in the general population. |
| No changes are suggested in the management of patients with stable ITP compared to what was advised before the SARS-CoV-2 pandemic. |
| We suggest a platelet threshold of 30 × 109/L in adults with newly diagnosed ITP who are asymptomatic or have minor mucocutaneous bleeding to begin treatment with steroids. |
| The use of immunosuppressants is discouraged unless there is no other therapeutic option. |
| Patients with ITP are not contraindicated for vaccination against COVID-19. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.